滚动资讯
FierceBiotechWave crashes after obesity trial tracks 1% dip in body weight over 6 monthsFierceBiotechPulmatrix picked for reverse merger with anti-aging biotech weeks after Cullgen deal collapsesFierceBiotechOrbiMed-backed Pinnacle adds $89M series B to power oral peptide pipelineFierceBiotechPhilips AI cath lab copilot nets FDA clearanceThermo FisherThermo Fisher Scientific (TMO) 是目前最值得买入的稳健型股票之一吗？- 雅虎财经BioPharma DiveFDA clears Denali drug in ‘clear step’ for rare disease biotechsEndpoints NewsWave crashes on obesity disappointmentLonza NewsBRIEF—Lonza launches new development lab in Singapore - The Pharma LetterBioPharma DiveWave crashes on obesity drug update; Kodiak’s reboot pays dividendsEndpoints NewsKodiak’s Phase 3 eye drug success; Innate discontinues anti-CD20 programEndpoints NewsLimbic aims to show AI beats humans in delivering therapyEndpoints NewsPost-Hoc: It’s time to make ACIP serious again
FierceBiotech 2026年3月26日

Innate在1/2期试验中终止NK细胞衔接器研究，作为持续管线调整的一部分。

Innate在1/2期试验中终止NK细胞衔接器研究，作为持续管线调整的一部分。

原文
暂时没有全文，请查看原始来源。

目录

59 全部